tbuckley/cabot-search huggingface dataset:
Neurological injuries in boxers: the use of tests
Authors: L. Charnas
Journal: JAMA (1990)

<h3>To the Editor. —</h3> Boxing is a dangerous sport. Neurological injury is preeminent among the dangers and is of two general types, acute and chronic.<sup>1</sup>The medical approaches to minimize the consequences of acute neurological damage are in wide use for the management of head trauma and generate little controversy in their application to boxing.<sup>2</sup> There is little consensus, however, about the optimal approach for early detection of chronic brain injury. We share the widely (but not universally) held belief that identifying and suspending athletes with early signs of damage to the central nervous system or congenital anatomic defects that clearly predispose to further injury are both laudable and effective. The New York State Athletic Commission has adopted an approach that requires an electroencephalogram and cranial computed tomographic scan as conditions for licensure. The electroencephalogram has low sensitivity and specificity for the types of chronic damage to the
Autologous stem cell transplantation (autoSCT) as first-line therapy in peripheral T cell lymphomas (PTCL): Results of a prospective multicenter study
Authors: P. Reimer, T. Rüdiger, H. Einsele, E. Geissinger, F. Weissinger, C. Nerl, N. Schmitz, A. Engert, H. Müller-Hermelink, M. Wilhelm
Journal: Journal of Clinical Oncology (2008)

8515 Background: Peripheral T-cell lymphomas (PTCL) represent a rare group of malignancies that show a poor outcome following conventional chemotherapy. However, the role of myeloablative therapy and autologous stem cell transplantation (autoSCT) is still unclear. Therefore, we initiated the first prospective multicenter phase II study on upfront autoSCT in PTCL and recently reported good feasibility and efficacy of this therapeutic approach. Here we present the final analysis of the study. Methods: The treatment regimen consisted of 4–6 cycles CHOP followed by induction therapy of either the DexaBEAM or the ESHAP and stem cell collection. Patients in complete (CR) or a partial remission (PR) underwent myeloablative radiochemotherapy (hyperfractionated total body irradiation and high-dose cyclophosphamide) followed by autoSCT. Results: From June 2000 to April 2006, 83 patients (pts) were enrolled into the study. The main PTCL subgroups were PTCL not specified (n= 32) and angioimmunoblastic T cell lymphoma (n= 27). Fifty-five of the 83 pts (66%) were transplanted. The main reason for not receiving autotransplantation was progressive disease. In an intent-to-treat analysis the overall response rate following myeloablative therapy was 66% (56% CR, 8% PR, respectively). With a median follow-up of 33 months, 43 patients are alive, the estimated 3-year OS (overall survival) and 3-year DFS (disease-free survival) for patients in CR (calculated from CR to the date of relapse) were 53%, and 36%, respectively. Conclusions: Our data suggest a substantial impact on outcome for upfront autoSCT in PTCL and should be further evaluated in randomised trials. However, pretransplant treatment needs to be improved to increase the transplantation rate. No significant financial relationships to disclose.
REPORTS FROM HOSPITALS.
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In Reply:
Authors: Mark N. Levine, Agnes Y.Y. Lee, Ajay K. Kakkar
Journal: Journal of Clinical Oncology (2005)

IN REPLY:Ferretti et al state that patients with malignancy and venous thromboembolism (VTE) treated with oral anticoagulant therapy "possibly" have an increased risk of recurrent VTE compared with patients without malignancy.The literature is consistent that cancer patients with acute VTE who are treated with long-term oral anticoagulant therapy have an increased risk of recurrent VTE compared with those without cancer. 1,2They are also somewhat tentative concerning secondary prophylaxis with lowmolecular-weight heparin (LMWH).The results of the trial by Lee et al, which compared long-term dalteparin LMWH with oral anticoagulant therapy in cancer patients with acute VTE demonstrated a 52% relative reduction in recurrent thromboembolism in favor of LMWH, which was highly statistically significant. 3hey make the point that in our recent report, we used all-cause mortality rather than cancer-related mortality. 4he convention in randomized trials in oncology is gener-
Relevance of Molecular Markers in Prostate Cancer
Authors: Edward P. Gelmann
Journal: Annals of Internal Medicine (2009)

Letters15 December 2009Relevance of Molecular Markers in Prostate CancerEdward P. Gelmann, MD and Susan M. Henshall, PhDEdward P. Gelmann, MDFrom Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032; and Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales 2010, Australia.Search for more papers by this author and Susan M. Henshall, PhDFrom Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032; and Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales 2010, Australia.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-151-12-200912150-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. Concato and colleagues make 3 major points. First, they say that their study determined whether marker status at diagnosis (vs. after surgery) predicted actual mortality and emphasized the importance of not assuming that biochemical failure is an outcome equivalent to mortality. Second, they explain that their results can guide future research on biological mechanisms and suggest new approaches to therapy. Third, they cite other reviews as affirming the importance of the 3 markers they highlighted: P53, BCL2, and microvessel density. We commend Dr. Concato and colleagues for assembling a large and important study cohort. However, in trying ...References1. Henry NL, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist. 2006;11:541-52. [PMID: 16794234] CrossrefMedlineGoogle Scholar2. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180-4. [PMID: 16106022] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Edward P. Gelmann, MD; Susan M. Henshall, PhDAffiliations: From Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032; and Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales 2010, Australia.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoClinically Relevant Prognostic Markers for Prostate Cancer: The Search Goes On Edward P. Gelmann and Susan M. Henshall Relevance of Molecular Markers in Prostate Cancer John Concato , Edward Uchio , and Carolyn K. Wells Metrics 15 December 2009Volume 151, Issue 12Page: 894-895KeywordsChemotherapyCohort studiesConflicts of interestForecastingHormonal therapyMortalityProstate cancerProstate diseasesSurgeryTreatment guidelines ePublished: 15 December 2009 Issue Published: 15 December 2009 Copyright & PermissionsCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
THE ASSOCIATION OF TRAUMATISM AND INFECTION.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Primary Drug Resistance in Tuberculosis
Authors: Sol Katz
Journal: JAMA (1970)

The introduction of isoniazid for the treatment of tuberculosis was accompanied by justified warnings, based on previous experience with streptomycin, that its improper use would result in the rapid development of tubercle bacilli resistant to this potent agent. Improper use was tantamount to the administration of isoniazid as a single agent rather than as a part of a combined drug regimen. The concept of prolonged combination therapy with isoniazid as one of the agents has firm support experimentally and in controlled clinical trials. Furthermore, studies of bacterial genetics have established the patterns by which resistant bacilli develop. It is through the use of such combined therapy that the appearance of resistant mutants is discouraged. Thus, assuming proper case finding, intelligently applied chemotherapy should control the vast majority of cases of tuberculosis. Since many factors must be involved in the ultimate eradication of tuberculosis, not the least of which is social,
Tinnitus
Authors: Judith Skillman
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Problems in the identification of potential organ donors. Misconceptions and fallacies associated with donor cards
Authors: T. D. Overcast
Journal: JAMA (1984)

A survey of organ procurement programs and district attorneys' offices was undertaken in all 50 states and the District of Columbia to determine to what extent organ donor cards were effective in obtaining organs for purposes of transplantation. Results of the survey revealed that all 50 states and the District of Columbia have adopted some form of the Uniform Anatomical Gift Act (UAGA), but in 47 states, even when a signed donor card is available, surgeons still require family approval for removal of organs despite the fact that the provisions of the UAGA do not require this. In addition, it was found that while 44 states have a provision on their permanent drivers' licenses for organ donation, no state requires drivers to indicate whether they want to donate organs. While there is little information on the number of persons who actually carry donor cards, four states indicated that between 1.7% and 8.5% of their drivers were designated as donors. In Colorado, however, it was reported that 60% of all drivers are designated as donors. Nevertheless, in all states it was determined that few actual donors were carrying donor cards at the time of their death. It must therefore be concluded that while donor cards are an excellent educational medium and certainly facilitate the activities of transplant coordination, they are not an effective means of substantially increasing the supply of organs for transplantation. (<i>JAMA</i>1984;251:1559-1562)
Biography of McDowell.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Significant knowledge gap about non-alcoholic fatty liver disease (NAFLD) in real-world practices: a global survey of hepatologists, gastroenterologists, endocrinologists and primary care physicians
Authors: Zobair Younossi, Yusuf Yilmaz, Mohammed El Kassas, Vincent Wai-Sun Wong, Ajay Kumar Duseja, Nahúm Méndez-Sanchez, Jacob George, Wah-Kheong Chan, Laurent Castera, Marco Arrese, Khaled Alswat, Hirokazu Takahashi, Manuel Romero Gomez, Janus Ong, Mariam Ziayee, Issah Younossi, Andrei Racila, Maria Stepanova
Journal: Journal of Hepatology (2020)
Rare Tumors in Kids May Respond to Tazemetostat
Journal: Cancer Discovery (2017)

In a phase I trial of the EZH2 inhibitor tazemetostat, children with INI1-deficient tumors-including relapsed or refractory malignant rhabdoid tumors, atypical teratoid rhabdoid tumors, epithelioid sarcomas, and poorly differentiated chordomas-responded well to treatment, with some experiencing durable responses.
Parotid swellings.
Journal: BMJ (1970)

MEDICAL JOL lonely, unhappy women with few or no friends in the block, and their children spent most of their days inside the flat.There was no place for them to play outside safe enough for the mother to leave them unsupervised.What such families wanted was "a place of our own with a back garden."Families with teenage or grown-up children were much more content.This report adds further weight to the case against tall flats as a solution to housing problems.D. M. Fanning2 has shown that flat dwellers are unhealthier than families who live in houses, and he, too, suggested that they were unhappier as well.The N.S.P.C.C. study found that balcony flats seem to
Monoclonal antibodies to recombinant Der f 2 and development of a two-site ELISA sensitive to major Der f 2 isoallergen in Korea
Authors: K.Y. Jeong, H.S. Jin, S.H. Oh, C.-S. Hong, I.-Y. Lee, H.-I. Ree, T.-S. Yong
Journal: Allergy (2002)
Cardiac Troponin T and Point-of-Care Testing for Myocardial Infarction-Reply
Authors: Elliott M. Antman
Journal: JAMA (1995)

<h3>In Reply.</h3> —To our knowledge, our article is the first clinical report on the functional characteristics of the rapid cTnT assay. In addition to apparent misinterpretation of some of our statements, Drs Eisenbrey and Artiss raised concerns that are uncommonly harsh for the initial report of a new diagnostic test. Although they quote a false-positive rate of 35% for the rapid cTnT assay, the data contained in the Table in our article actually indicate false-positive rates of 5.3%, 0%, 0%, and 14.3% at 0 to 2, 2 to 4, 4 to 8, and more than 8 hours from the onset of chest pain, respectively. Furthermore, the concept of a false-positive result must be reconsidered when a more sensitive test for myocardial necrosis, such as cTnT, is compared with a "gold standard" of CK-MB, which is known to be insensitive to small infarcts. In addition, CK-MB may be increased in the
Chemical Code Determined for Nucleic Acid
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
External validation of a novel trifecta system in predicting oncologic and functional outcomes of partial nephrectomy: Results of a multicentric series
Authors: U. Anceschi, M. Puglisi, R.S. Flammia, A. Brassetti, L. Luciani, G. Tuderti, A. Tufano, D. Mattevi, M.C. Ferriero, T. Cai, A.M. Bove, C. Leonardo, S. Guaglianone, R. Mastroianni, V. Vattovani, F. Proietti, M. Gallucci, G. Malossini, G. Simone
Journal: European Urology (2021)
Biokinetics of Nuclear Fuel Compounds and Biological Effects of Nonuniform Radiation
Authors: Sakari Lang, Kristina Servomaa, Veli-Matti Kosma, Tapio Rytomaa
Journal: Environmental Health Perspectives (1995)

Environmental releases of insoluble nuclear fuel compounds may occur at nuclear power plants during normal operation, after nuclear power plant accidents, and as a consequence of nuclear weapons testing. For example, the Chernobyl fallout contained extensive amounts of pulverized nuclear fuel composed of uranium and its nonvolatile fission products. The effects of these highly radioactive particles, also called hot particles, on humans are not well known due to lack of reliable data on the extent of the exposure. However, the biokinetics and biological effects of nuclear fuel compounds have been investigated in a number of experimental studies using various cellular systems and laboratory animals. In this article, we review the biokinetic properties and effects of insoluble nuclear fuel compounds, with special reference to UO2, PuO2, and nonvolatile, long-lived beta-emitters Zr, Nb, Ru, and Ce. First, the data on hot particles, including sources, dosimetry, and human exposure are discussed. Second, the biokinetics of insoluble nuclear fuel compounds in the gastrointestinal tract and respiratory tract are reviewed. Finally, short- and long-term biological effects of nonuniform alpha- and beta-irradiation on the gastrointestinal tract, lungs, and skin are discussed.
The Cover
Authors: Rodrigo Dominguez
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NORTH DAKOTA MEDICAL ASSOCIATION
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal